Loading…

Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study

MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® appli...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-10, Vol.23 (19), p.11470
Main Authors: Benfante, Alida, Sousa-Pinto, Bernardo, Pillitteri, Gianluca, Battaglia, Salvatore, Fonseca, Joao, Bousquet, Jean, Scichilone, Nicola
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3
cites cdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3
container_end_page
container_issue 19
container_start_page 11470
container_title International journal of molecular sciences
container_volume 23
creator Benfante, Alida
Sousa-Pinto, Bernardo
Pillitteri, Gianluca
Battaglia, Salvatore
Fonseca, Joao
Bousquet, Jean
Scichilone, Nicola
description MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.
doi_str_mv 10.3390/ijms231911470
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d42c52ef40e749faa2167cd98807a539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d42c52ef40e749faa2167cd98807a539</doaj_id><sourcerecordid>2725199398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiNERUvhyN0SFy4BfyYxB6RQ8VG1FUhbzpZjj3e9ctaL7RTtn-JH8MvIshXq9uRXnkePZkZTVa8IfsuYxO_8esyUEUkIb_GT6oxwSmuMm_bpg3xaPc95jTFlVMhn1Slr5tS25Kwy_XYbvNGDD77sUHSorADd9Iuruvfpz28011GJaAF3kAD1uaxGjW4T6AIW_fJlhT76GOLSG3QTA5gpQH6PevTdh1jQokx296I6cTpkeHn_nlc_Pn-6vfhaX3_7cnnRX9eGi67U1nQNlYILynk7aItpSxtqLR4wJsJoYQfqQDqhB2ykk1wYMkfBqZbOmYGdV5cHr416rbbJjzrtVNRe_fuIaal0Kt4EUJZTIyg4jqHl0mlNSdMaK7sOt1owObs-HFzbaRjBGtiUpMOR9Liy8Su1jHdKikbyBs-CN_eCFH9OkIsafTYQgt5AnLKahxNESia7GX39CF3HKW3mVe0pTjvBuj1VHyiTYs4J3P9mCFb7U1BHp8D-Amt8pZk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2724285388</pqid></control><display><type>article</type><title>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Benfante, Alida ; Sousa-Pinto, Bernardo ; Pillitteri, Gianluca ; Battaglia, Salvatore ; Fonseca, Joao ; Bousquet, Jean ; Scichilone, Nicola</creator><creatorcontrib>Benfante, Alida ; Sousa-Pinto, Bernardo ; Pillitteri, Gianluca ; Battaglia, Salvatore ; Fonseca, Joao ; Bousquet, Jean ; Scichilone, Nicola</creatorcontrib><description>MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms231911470</identifier><identifier>PMID: 36232771</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Air monitoring ; Allergic rhinitis ; application ; Asthma ; Best practice ; biologic molecules ; Clinical outcomes ; Collaboration ; Conjunctivitis ; Correlation ; Disease control ; Dyspnea ; Hay fever ; Integrated delivery systems ; Patient compliance ; Patients ; Physicians ; Respiration ; Rhinitis ; severe asthma ; Telemedicine ; Trends ; visual analogue scales</subject><ispartof>International journal of molecular sciences, 2022-10, Vol.23 (19), p.11470</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</citedby><cites>FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</cites><orcidid>0000-0002-0887-8796 ; 0000-0001-6400-6573 ; 0000-0002-2867-917X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2724285388/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2724285388?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids></links><search><creatorcontrib>Benfante, Alida</creatorcontrib><creatorcontrib>Sousa-Pinto, Bernardo</creatorcontrib><creatorcontrib>Pillitteri, Gianluca</creatorcontrib><creatorcontrib>Battaglia, Salvatore</creatorcontrib><creatorcontrib>Fonseca, Joao</creatorcontrib><creatorcontrib>Bousquet, Jean</creatorcontrib><creatorcontrib>Scichilone, Nicola</creatorcontrib><title>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</title><title>International journal of molecular sciences</title><description>MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.</description><subject>Air monitoring</subject><subject>Allergic rhinitis</subject><subject>application</subject><subject>Asthma</subject><subject>Best practice</subject><subject>biologic molecules</subject><subject>Clinical outcomes</subject><subject>Collaboration</subject><subject>Conjunctivitis</subject><subject>Correlation</subject><subject>Disease control</subject><subject>Dyspnea</subject><subject>Hay fever</subject><subject>Integrated delivery systems</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Physicians</subject><subject>Respiration</subject><subject>Rhinitis</subject><subject>severe asthma</subject><subject>Telemedicine</subject><subject>Trends</subject><subject>visual analogue scales</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1v1DAQhiNERUvhyN0SFy4BfyYxB6RQ8VG1FUhbzpZjj3e9ctaL7RTtn-JH8MvIshXq9uRXnkePZkZTVa8IfsuYxO_8esyUEUkIb_GT6oxwSmuMm_bpg3xaPc95jTFlVMhn1Slr5tS25Kwy_XYbvNGDD77sUHSorADd9Iuruvfpz28011GJaAF3kAD1uaxGjW4T6AIW_fJlhT76GOLSG3QTA5gpQH6PevTdh1jQokx296I6cTpkeHn_nlc_Pn-6vfhaX3_7cnnRX9eGi67U1nQNlYILynk7aItpSxtqLR4wJsJoYQfqQDqhB2ykk1wYMkfBqZbOmYGdV5cHr416rbbJjzrtVNRe_fuIaal0Kt4EUJZTIyg4jqHl0mlNSdMaK7sOt1owObs-HFzbaRjBGtiUpMOR9Liy8Su1jHdKikbyBs-CN_eCFH9OkIsafTYQgt5AnLKahxNESia7GX39CF3HKW3mVe0pTjvBuj1VHyiTYs4J3P9mCFb7U1BHp8D-Amt8pZk</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Benfante, Alida</creator><creator>Sousa-Pinto, Bernardo</creator><creator>Pillitteri, Gianluca</creator><creator>Battaglia, Salvatore</creator><creator>Fonseca, Joao</creator><creator>Bousquet, Jean</creator><creator>Scichilone, Nicola</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0887-8796</orcidid><orcidid>https://orcid.org/0000-0001-6400-6573</orcidid><orcidid>https://orcid.org/0000-0002-2867-917X</orcidid></search><sort><creationdate>20221001</creationdate><title>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</title><author>Benfante, Alida ; Sousa-Pinto, Bernardo ; Pillitteri, Gianluca ; Battaglia, Salvatore ; Fonseca, Joao ; Bousquet, Jean ; Scichilone, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Air monitoring</topic><topic>Allergic rhinitis</topic><topic>application</topic><topic>Asthma</topic><topic>Best practice</topic><topic>biologic molecules</topic><topic>Clinical outcomes</topic><topic>Collaboration</topic><topic>Conjunctivitis</topic><topic>Correlation</topic><topic>Disease control</topic><topic>Dyspnea</topic><topic>Hay fever</topic><topic>Integrated delivery systems</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Physicians</topic><topic>Respiration</topic><topic>Rhinitis</topic><topic>severe asthma</topic><topic>Telemedicine</topic><topic>Trends</topic><topic>visual analogue scales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benfante, Alida</creatorcontrib><creatorcontrib>Sousa-Pinto, Bernardo</creatorcontrib><creatorcontrib>Pillitteri, Gianluca</creatorcontrib><creatorcontrib>Battaglia, Salvatore</creatorcontrib><creatorcontrib>Fonseca, Joao</creatorcontrib><creatorcontrib>Bousquet, Jean</creatorcontrib><creatorcontrib>Scichilone, Nicola</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benfante, Alida</au><au>Sousa-Pinto, Bernardo</au><au>Pillitteri, Gianluca</au><au>Battaglia, Salvatore</au><au>Fonseca, Joao</au><au>Bousquet, Jean</au><au>Scichilone, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study</atitle><jtitle>International journal of molecular sciences</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>23</volume><issue>19</issue><spage>11470</spage><pages>11470-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>36232771</pmid><doi>10.3390/ijms231911470</doi><orcidid>https://orcid.org/0000-0002-0887-8796</orcidid><orcidid>https://orcid.org/0000-0001-6400-6573</orcidid><orcidid>https://orcid.org/0000-0002-2867-917X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2022-10, Vol.23 (19), p.11470
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d42c52ef40e749faa2167cd98807a539
source Publicly Available Content Database; PubMed Central
subjects Air monitoring
Allergic rhinitis
application
Asthma
Best practice
biologic molecules
Clinical outcomes
Collaboration
Conjunctivitis
Correlation
Disease control
Dyspnea
Hay fever
Integrated delivery systems
Patient compliance
Patients
Physicians
Respiration
Rhinitis
severe asthma
Telemedicine
Trends
visual analogue scales
title Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A45%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Applicability%20of%20the%20MASK-Air%C2%AE%20App%20to%20Severe%20Asthma%20Treated%20with%20Biologic%20Molecules:%20A%20Pilot%20Study&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Benfante,%20Alida&rft.date=2022-10-01&rft.volume=23&rft.issue=19&rft.spage=11470&rft.pages=11470-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms231911470&rft_dat=%3Cproquest_doaj_%3E2725199398%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c458t-dc86295452447bad027262dd0b0015ca5db2fe9f5ab0c9f945c1ab0542a9ffcb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2724285388&rft_id=info:pmid/36232771&rfr_iscdi=true